NASDAQ$FULC
Fulcrum Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Fulcrum Therapeutics reported a net loss in Q2 2025 driven by operating expenses after suspending losmapimod development.
For the three months ended June 30, 2025, Fulcrum recorded zero collaboration revenue and a net loss of $17.3 million, compared to net income in the prior year due to an $80 million upfront payment. Research and development expenses were $13.0 million and general and administrative expenses were $6.8 million. The company ended the quarter with $214.1 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028.
- Net loss of $17.3 million for Q2 2025 with no collaboration revenue recognized.
- R&D expenses totaled $13.0 million focused on pociredir for sickle cell disease.
- Cash position of $214.1 million provides runway into 2028.
- Phase 1b pociredir data showed HbF increases; 20 mg cohort data expected by year-end 2025.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$0
Forward guidance
Cash runway into 2028; 20 mg pociredir cohort data expected by end of 2025; IND filing for DBA program planned for Q4 2025.
Tailwinds
- Strong cash position supports multiple programs into 2028.
- Positive Phase 1b pociredir data with HbF increases and safety profile.
- Ongoing 20 mg dose cohort with data readout by year end.
Headwinds
- No revenue from Sanofi collaboration after termination.
- Prior Phase 3 losmapimod failure led to program suspension.
- Narrowed patient criteria may slow enrollment in pociredir trial.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro